Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Depemokimab (GSK3511294) Administered Subcutaneously as Add on Maintenance Treatment of Asthma With Type 2 Inflammation Characterised by an Eosinophilic Phenotype in Participants Aged 6 to 11 Years Old

NCT07671001 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07671001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07671001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Depemokimab (GSK3511294) Administered Subcutaneously as Add on Maintenance Treatment of Asthma With Type 2 Inflammation Characterised by an Eosinophilic Phenotype in Participants Aged 6 to 11 Years Old
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Recruiting
Start date
June 25, 2026
Completion date
November 24, 2028
Enrollment
34 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

asthma